

# Anti-DLL4 Reference Antibody (Smart Targeting patent anti-DLL4)

Recombinant Antibody  
Catalog # APR10883

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">Q9NR61</a>
<b>Reactivity</b>	Human
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1
<b>Calculated MW</b>	74605

## Additional Information

---

<b>Target/Specificity</b>	DLL4
<b>Endotoxin Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.


## Protein Information

---


<b>Name</b>	DLL4
<b>Function</b>	Involved in the Notch signaling pathway as Notch ligand (PubMed: <a href="#">11134954</a> ). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed: <a href="#">20616313</a> ). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed: <a href="#">17728344</a> ).
<b>Cellular Location</b>	Cell membrane; Single-pass type I membrane protein
<b>Tissue Location</b>	Expressed in vascular endothelium.

## Images

---



Anti-DLL4 Reference Antibody (Smart Targeting patent anti-DLL4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-DLL4 Reference Antibody (Smart Targeting patent anti-DLL4) is more than 95% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.